New hope for depression when standard drugs fail
NCT ID NCT03870776
Summary
This study tested whether a daily oral medication called MAP4343 could help reduce symptoms in people with major depression who did not respond to at least two standard antidepressant treatments. For 6 weeks, 126 participants either received MAP4343 or a placebo pill, without knowing which one they were taking. Researchers measured changes in depression and anxiety scores, along with safety checks, to see if the new drug offered relief where other treatments had not.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center
Paris, 75013, France
-
CHD Vendée
La Roche-sur-Yon, 85000, France
-
CHRU Tours
Tours, 37000, France
-
CHU Angers
Angers, 49900, France
-
CHU Besançon
Besançon, 25000, France
-
CHU Henri Laborit
Poitiers, 86000, France
-
CHU Nantes
Nantes, 44000, France
-
Cabinet Médical Ambroise Paré
Élancourt, 78990, France
-
Hôpital Fontan 1
Lille, 59000, France
-
Hôpital Ste Anne
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.